Bone Therapeutics Reports Initial Efficacy from PREOB® Phase IIA Trial
Initial 12-month efficacy results from a Phase IIA trial demonstrate positive effects on pain and osteoporosis blood markers from a single administration of Bone Therapeutics’ PREOB® autologous osteoblastic cell therapy. Mar 29, 2016